No Data
No Data
ADC Therapeutics Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Analysts Are Updating Their ADC Therapeutics SA (NYSE:ADCT) Estimates After Its Second-Quarter Results
ADC Therapeutics Price Target Maintained With a $8.00/Share by RBC Capital
ADC Therapeutics Analyst Ratings
RBC Capital Reaffirms Their Buy Rating on ADC Therapeutics (ADCT)
ADC Therapeutics: A Strong Buy on Robust Trials and Solid Financials
No Data